Vanda Pharmaceuticals Management

Management criteria checks 3/4

Vanda Pharmaceuticals' CEO is Mihael Polymeropoulos, appointed in May 2003, has a tenure of 21.5 years. total yearly compensation is $3.72M, comprised of 24.1% salary and 75.9% bonuses, including company stock and options. directly owns 2.14% of the company’s shares, worth $6.36M. The average tenure of the management team and the board of directors is 5.8 years and 5.1 years respectively.

Key information

Mihael Polymeropoulos

Chief executive officer

US$3.7m

Total compensation

CEO salary percentage	24.1%
CEO tenure	21.5yrs
CEO ownership	2.1%
Management average tenure	5.8yrs
Board average tenure	5.1yrs

Recent management updates

Recent updates

Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids

Sep 05

Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over

Aug 08

Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest

Jun 18

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

Apr 05

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Feb 15

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Feb 13

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Feb 10

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Nov 11

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

May 12

CEO Compensation Analysis

How has Mihael Polymeropoulos's remuneration changed compared to Vanda Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$16m
Jun 30 2024	n/a	n/a	-US$11m
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$4m	US$897k	US$3m
Sep 30 2023	n/a	n/a	US$12m
Jun 30 2023	n/a	n/a	US$15m
Mar 31 2023	n/a	n/a	US$16m
Dec 31 2022	US$4m	US$815k	US$6m
Sep 30 2022	n/a	n/a	US$6m
Jun 30 2022	n/a	n/a	US$11m
Mar 31 2022	n/a	n/a	US$18m
Dec 31 2021	US$6m	US$769k	US$33m
Sep 30 2021	n/a	n/a	US$34m
Jun 30 2021	n/a	n/a	US$32m
Mar 31 2021	n/a	n/a	US$32m
Dec 31 2020	US$3m	US$746k	US$23m
Sep 30 2020	n/a	n/a	US$19m
Jun 30 2020	n/a	n/a	US$114m
Mar 31 2020	n/a	n/a	US$117m
Dec 31 2019	US$4m	US$721k	US$116m
Sep 30 2019	n/a	n/a	US$122m
Jun 30 2019	n/a	n/a	US$28m
Mar 31 2019	n/a	n/a	US$22m
Dec 31 2018	US$4m	US$700k	US$25m
Sep 30 2018	n/a	n/a	US$13m
Jun 30 2018	n/a	n/a	US$1m
Mar 31 2018	n/a	n/a	-US$5m
Dec 31 2017	US$6m	US$675k	-US$16m

Compensation vs Market: Mihael's total compensation ($USD3.72M) is above average for companies of similar size in the US market ($USD1.46M).

Compensation vs Earnings: Mihael's compensation has been consistent with company performance over the past year.

CEO

Mihael Polymeropoulos (64 yo)

21.5yrs

Tenure

US$3,720,215

Compensation

Dr. Mihael H. Polymeropoulos, M.D., founded Vanda Pharmaceuticals, Inc. in 2003. He serves as Chairman of The Board at Vanda Pharmaceuticals Inc since June 2021 and has been its Chief Executive Officer, Pr...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mihael Polymeropoulos	Founder	21.5yrs	US$3.72m	2.14% $ 6.4m
Kevin Moran	Senior VP	4.7yrs	US$1.32m	0.095% $ 281.7k
Timothy Williams	Senior VP	6.3yrs	US$1.40m	0.039% $ 115.9k
Joakim Wijkstrom	Senior VP & Chief Marketing Officer	5.3yrs	US$1.36m	0.085% $ 253.3k
Gunther Birznieks	Senior Vice President of Business Development	7.7yrs	US$1.37m	0.24% $ 710.2k
Scott Howell	Chief People Officer	5.3yrs	no data	no data

5.8yrs

Average Tenure

55yo

Average Age

Experienced Management: VNDA's management team is seasoned and experienced (5.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Mihael Polymeropoulos	Founder	21.5yrs	US$3.72m	2.14% $ 6.4m
Richard Dugan	Lead Independent Director	18.9yrs	US$332.50k	0.14% $ 409.2k
Tage Honore	Independent Director	1.7yrs	US$602.43k	0.011% $ 33.6k
Anne Ward	Independent Director	5.1yrs	US$302.50k	0.038% $ 112.0k
Stephen Mitchell	Independent Director	4.8yrs	US$282.50k	0.042% $ 123.8k
Phaedra Chrousos	Independent Director	5.1yrs	US$300.00k	0.043% $ 126.9k

5.1yrs

Average Tenure

68yo

Average Age

Experienced Board: VNDA's board of directors are considered experienced (5.1 years average tenure).

Vanda Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Insider recently sold US$73k worth of stock

Founder notifies of intention to sell stock

Senior VP recently sold US$96k worth of stock

Senior VP notifies of intention to sell stock

Recent updates

Vanda Pharmaceuticals Inc. Revises Revenue Guidance for the Full Year 2024

Vanda Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 06, 2024

Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA for approximately $490 million.

FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis

Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids

Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over

Vanda Pharmaceuticals Inc. Reinstates Financial Guidance for the Full Year 2024

Vanda Pharmaceuticals Inc. to Report Q2, 2024 Results on Jul 31, 2024

Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index

Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc. (NYSE:BLK), Butler Hall Capital LLC, Shareholder Capital LLC and others.

Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA).

Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest

Cycle Pharmaceuticals Limited made a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) for approximately $490 million.

Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc. (NYSE:BLK), Butler Hall Capital LLC, Shareholder Capital LLC and others.

Vanda Pharmaceuticals Inc. Reports Positive Results from A Second Phase III Study of Tradipitant in Motion Sickness

First quarter 2024 earnings released: US$0.072 loss per share (vs US$0.057 profit in 1Q 2023)

Price target increased by 23% to US$5.21

Vanda Pharmaceuticals Inc. to Report Q1, 2024 Results on May 08, 2024

Future Pak, Ltd. submits a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others for approximately $450 million.

Future Pak, Ltd. submits a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others for approximately $450 million.

Consensus EPS estimates fall from profit to US$0.06 loss, revenue upgraded

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

New minor risk - Share price stability

Vanda Pharmaceuticals' Fanapt (Iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

Insider recently sold US$73k worth of stock

Founder notifies of intention to sell stock

Vanda Pharmaceuticals Announces FDA Update for Supplemental NDA for HETLIOZ in the Treatment of Insomnia

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Consensus revenue estimates increase by 27%

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia

Vanda Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 07, 2024

Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Approval for VTR-297 for the Treatment of Onychomycosis

Vanda Pharmaceuticals Inc. Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

Now 21% undervalued after recent price drop

Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis

Now 21% undervalued after recent price drop

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Third quarter 2023 earnings released: EPS: US$0.002 (vs US$0.058 in 3Q 2022)

Vanda Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 08, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vanda Pharmaceuticals Inc. to Report Q2, 2023 Results on Jul 27, 2023

Senior VP recently sold US$96k worth of stock

Senior VP notifies of intention to sell stock

Vanda Pharmaceuticals Inc Reports Results from a Phase III study of Tradipitant in Motion Sickness

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

Vanda Pharmaceuticals Inc. Responds to the Ruling in its Hetlioz(R) Abbreviated New Drug Application Appeal

First quarter 2023 earnings released: EPS: US$0.057 (vs US$0.12 loss in 1Q 2022)

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age